RDHL
RedHill Biopharma Ltd.

7,335
Mkt Cap
$5.46M
Volume
89,524.00
52W High
$8.75
52W Low
$1.06
PE Ratio
-0.02
RDHL Fundamentals
Price
$1.57
Prev Close
$1.64
Open
$1.67
50D MA
$1.63
Beta
0.80
Avg. Volume
2.73M
EPS (Annual)
-$6.73
P/B
-0.82
Rev/Employee
$230,890.69
Loading...
Loading...
News
all
press releases
RedHill Biopharma Receives Nasdaq Staff Determination Notification
RedHill Biopharma Receives Nasdaq Staff Determination Notification RedHill Biopharma Receives Nasdaq Staff Determination Notification PR Newswire TEL AVIV, Israel and RALEIGH, N.C., Oct. 22, 2025 On...
PR Newswire·5d ago
News Placeholder
More News
News Placeholder
RedHill Biopharma Logs Best Session In Over A Year After $10M Legal Victory — Retail Sees Bullish Triggers Ahead
The stock rallied after the New York Supreme Court reaffirmed RedHill’s $10 million award in its dispute with Kukbo.
Stocktwits·28d ago
News Placeholder
RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties
RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties RedHill Licenses RHB-102 for...
PR Newswire·8mo ago
News Placeholder
RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer
RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate...
PR Newswire·9mo ago
News Placeholder
RedHill's Talicia Adds 8 Million Lives With Coverage by Humana's Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published
RedHill's Talicia Adds 8 Million Lives With Coverage by Humana's Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published RedHill's Talicia Adds 8 Million Lives...
PR Newswire·9mo ago
News Placeholder
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development
Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development Radioprotective Activity of RedHill's...
PR Newswire·11mo ago
News Placeholder
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court
RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court...
PR Newswire·11mo ago
News Placeholder
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors
Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry...
PR Newswire·1y ago
News Placeholder
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND
RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND PR Newswire...
PR Newswire·1y ago
News Placeholder
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury
RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury RedHill Announces Collaboration with a Leading...
PR Newswire·1y ago

Latest RDHL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.